Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

J. B. Chemicals & Pharmaceuticals Limited manufactures and markets pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients (API) in India and internationally. The company's API product portfolio includes diclofenac sodium, diethylamine, acid, and potassium; nifedipine, atenolol, and cilnidipine; and ciprofloxacin, cetirizine, and meclizine HCI. It also provides dosage forms, such as tablets, lozenges, injectables, gels, creams, ointments, liquid herbal syrups, cold rubs, eye drops, troches, and capsules; and soft-centered, powder, medicated, and herbal lozenges, as well as various pharmaceutical dosage forms. In addition, it offers a range of contrast media products, including x-ray, magnetic resonance imaging (MRI), and ultrasound scanners; and contract manufacturing services. The company provides its products in gastroenterology, anti-infectives, wound care, neonatology and pediatrics, gynaecology, dental, vitamins and minerals, hypertension, diabetes, nephrology, respiratory, pain-analgesic, dermatology, antivirals, lozenges, and contrast media and radio diagnostic therapeutic areas. J. B. Chemicals & Pharmaceuticals Limited was incorporated in 1976 and is headquartered in Mumbai, India.

Revenue projections:

Revenue projections for JBCHEPHARM
Revenue projections for JBCHEPHARM

J. B. Chemicals & Pharmaceuticals Limited is projected to see a decline in revenue compared to last year, which could lead to investor caution. A drop in earnings is often viewed as a negative signal for profitability, making it more difficult for the company to maintain investor confidence in its financial health.

Financial Ratios:

currentRatio 3.04100
forwardPE 27.70145
debtToEquity 0.81200
earningsGrowth 0.13700
revenueGrowth 0.10200
grossMargins 0.66397
operatingMargins 0.18958
trailingEps 41.57000
forwardEps 0.00000

J. B. Chemicals & Pharmaceuticals Limited's current ratio of 3.041 means the company has enough liquidity to meet its short-term debt obligations. With sufficient cash reserves and current assets, J. B. Chemicals & Pharmaceuticals Limited can comfortably cover its liabilities, reflecting a strong financial outlook.
JBCHEPHARM's Forward PE ratio is in a good range, reflecting a reasonable balance between stock price and earnings. The stock is not overpriced, leaving room for growth, which suggests potential for investors looking to capitalize on future value appreciation.
JBCHEPHARM's positive earnings and revenue growth suggest that the company is expected to expand its business. This reflects a healthy financial outlook, as JBCHEPHARM's increasing profits and sales signal further growth in the near future.

Price projections:

Price projections for JBCHEPHARM
Price projections for JBCHEPHARM

Over time, JBCHEPHARM's price projections have been consistently revised lower. This suggests analysts are becoming less optimistic about the company's future prospects and are adjusting their forecasts accordingly.

Insider Transactions:

Insider Transactions for JBCHEPHARM
Insider Transactions for JBCHEPHARM


J. B. Chemicals & Pharmaceuticals Limited experienced 47 sell transactions with market price of 1776.8223435422208 per share.There were no sell transactions during the given timeframe.With more buys than sells around JBCHEPHARM's current price, there seems to be increased confidence among investors. This shift may indicate a favorable outlook, as the buying behavior suggests optimism for the stock's future growth or resilience.

Recommendation changes over time:

Recommendations trend for JBCHEPHARM
Recommendations trend for JBCHEPHARM


Analysts are favoring JBCHEPHARM with a buy bias, highlighting the stock's potential as a solid investment. This recommendation might drive more investors to consider JBCHEPHARM as a secure and profitable option for their money, contributing to a broader positive sentiment in the market.